Bulletin
Investor Alert

press release

Jan. 13, 2022, 4:05 p.m. EST

Regeneron to Report Fourth Quarter and Full Year 2021 Financial and Operating Results and Host Conference Call and Webcast on

TARRYTOWN, N.Y., Jan. 13, 2022 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN ) today announced that it will report its fourth quarter and full year 2021 financial and operating results on Friday, February 4, 2022, before the U.S. financial markets open.  The Company will host a conference call and simultaneous webcast at 8:30 AM Eastern Time that day.

Conference Call Information Participants may access the conference call live via webcast on the 'Investors and Media' page of Regeneron's website at  https://investor.regeneron.com/events-and-presentations . To participate via telephone, please register in advance at this link . Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique passcode and registrant ID that can be used to access the call.  A replay of the conference call and webcast will be archived on the Company's website for at least 30 days.

About   Regeneron Regeneron  /zigman2/quotes/203149337/composite REGN +0.61% is a leading biotechnology company that invents life-transforming medicines for people with serious diseases. Founded and led for over 30 years by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to nine FDA-approved treatments and numerous product candidates in development, almost all of which were homegrown in our laboratories. Our medicines and pipeline are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, pain, hematologic conditions, infectious diseases and rare diseases.

Regeneron is accelerating and improving the traditional drug development process through our proprietary  VelociSuite®  technologies, such as  VelocImmune® , which uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies, and through ambitious research initiatives such as the Regeneron Genetics Center, which is conducting one of the largest genetics sequencing efforts in the world.

For additional information about the company, please visit  www.regeneron.com  or follow @Regeneron on Twitter.

Contact Information: Investor Relations
Mark Hudson
914.847.3482
mark.hudson@regeneron.com

Corporate Communications
Christina Chan
914.847.8827
christina.chan@regeneron.com

Cision
View original content: https://www.prnewswire.com/news-releases/regeneron-to-report-fourth-quarter-and-full-year-2021-financial-and-operating-results-and-host-conference-call-and-webcast-on-301460682.html

SOURCE Regeneron Pharmaceuticals, Inc.

COMTEX_400488662/2454/2022-01-13T16:05:08

Is there a problem with this press release? Contact the source provider Comtex at editorial@comtex.com. You can also contact MarketWatch Customer Service via our Customer Center.

Copyright (C) 2022 PR Newswire. All rights reserved

/zigman2/quotes/203149337/composite
US : U.S.: Nasdaq
$ 661.14
+3.99 +0.61%
Volume: 544,265
May 20, 2022 4:00p
P/E Ratio
9.37
Dividend Yield
N/A
Market Cap
$72.63 billion
Rev. per Employee
$1.59M
loading...

Comtex

Partner Center

Link to MarketWatch's Slice.